Scholarlink

<p>This study aimed to evaluate the pharmacokinetics (PKs) for fixed-dose combination (FDC) of ezetimibe/rosuvastatin/telmisartan 10/20/80&#xa0;mg (test) compared to separate tablets of ezetimibe/rosuvastatin 10/20&#xa0;mg FDC and telmisartan 80&#xa0;mg (reference). A randomized, open-label, 4-period, 2-sequence replicated crossover study was conducted in healthy participants. Each treatment group received a single oral dose of test or reference drug in each period. PK samples during the 1st and 2nd periods were collected for all three drugs, while only telmisartan concentration was measured in the 3rd and 4th periods to evaluate intra-subject variability (ISV) of telmisartan. Geometric mean ratios (GMRs) of PK parameters and their 90% confidence intervals (CIs) were calculated with a linear mixed effect model between each treatment group. To account for the high ISV of telmisartan’s peak plasma concentration (<i>C</i><sub>max</sub>), the scaled average bioequivalence (SABE) approach was considered in this analysis.&#xa0;A total of 58 participants were randomized, and 49 participants completed the study. PK profiles were comparable between treatments. The GMR and 90% CIs (test-to-reference) of area under the time-concentration curve and <i>C</i><sub>max</sub> were 0.9835 (0.9260–1.0446) and 0.9873 (0.8830–1.1039) for free ezetimibe, and 0.9937 (0.9459–1.0440) and 1.0617 (0.9844–1.1415) for total ezetimibe. For rosuvastatin, corresponding values were 0.9465 (0.8883–1.0086) and 0.9062 (0.8135–1.0096); for telmisartan, 0.9728 (0.9315–1.0159) and 0.9724 (0.8846–1.0690), respectively. The result established equivalence without utilizing the SABE approach, although the ISV of telmisartan’s <i>C</i><sub>max</sub> was 40.7%.&#xa0;A FDC of ezetimibe/rosuvastatin/telmisartan 10/20/80&#xa0;mg demonstrated comparable pharmacokinetic profiles to corresponding separate treatments.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pharmacokinetic comparison of ezetimibe/rosuvastatin/telmisartan 10/20/80 mg fixed-dose combination versus coadministration of separate tablets in healthy participants

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月8日

查看全文
  • Seoyoung Goh,
  • Ki Young Huh,
  • SeungHwan Lee,
  • Joo-Youn Cho,
  • Kyung-Sang Yu

摘要

This study aimed to evaluate the pharmacokinetics (PKs) for fixed-dose combination (FDC) of ezetimibe/rosuvastatin/telmisartan 10/20/80 mg (test) compared to separate tablets of ezetimibe/rosuvastatin 10/20 mg FDC and telmisartan 80 mg (reference). A randomized, open-label, 4-period, 2-sequence replicated crossover study was conducted in healthy participants. Each treatment group received a single oral dose of test or reference drug in each period. PK samples during the 1st and 2nd periods were collected for all three drugs, while only telmisartan concentration was measured in the 3rd and 4th periods to evaluate intra-subject variability (ISV) of telmisartan. Geometric mean ratios (GMRs) of PK parameters and their 90% confidence intervals (CIs) were calculated with a linear mixed effect model between each treatment group. To account for the high ISV of telmisartan’s peak plasma concentration (Cmax), the scaled average bioequivalence (SABE) approach was considered in this analysis. A total of 58 participants were randomized, and 49 participants completed the study. PK profiles were comparable between treatments. The GMR and 90% CIs (test-to-reference) of area under the time-concentration curve and Cmax were 0.9835 (0.9260–1.0446) and 0.9873 (0.8830–1.1039) for free ezetimibe, and 0.9937 (0.9459–1.0440) and 1.0617 (0.9844–1.1415) for total ezetimibe. For rosuvastatin, corresponding values were 0.9465 (0.8883–1.0086) and 0.9062 (0.8135–1.0096); for telmisartan, 0.9728 (0.9315–1.0159) and 0.9724 (0.8846–1.0690), respectively. The result established equivalence without utilizing the SABE approach, although the ISV of telmisartan’s Cmax was 40.7%. A FDC of ezetimibe/rosuvastatin/telmisartan 10/20/80 mg demonstrated comparable pharmacokinetic profiles to corresponding separate treatments.